Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

Qiagen and Roche Bury the Hatchet on Dispute over DxS TheraScreen Assay Distribution

Roche retains existing distribution rights to KRAS and EGFR assays, while Qiagen will market products under its own label.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

Myriad Genetics Trial: Your Thoughts?

Do you agree with the Supreme Court’s decision in the Myriad case?

Suggest a Poll